1. Pink Sheet
  2. >>Market Access

Medicare Negotiation Workarounds: Lilly’s Ricks On Big Pharma Strategies For Small Molecule Drugs

 
• By Cathy Kelly

A vocal critic of the way Medicare price negotiation program treats small molecule drugs, the Lilly CEO and offers possible scenarios of how developers may react.

Lots Of Strategizing Going On • Source: Shutterstock

Pharma companies could develop multiple small molecule drugs for related indications, rather than focus on a single molecule, to allow for staggered launch dates that would protect some uses from Medicare price negotiation beginning nine years after approval, Eli Lilly and Company CEO David Ricks suggested during a JP Morgan webinar on the impact of the Inflation Reduction Act 14 June.

Key Takeaways

  • Pharmas could develop multiple molecules for different indications and stagger launch dates.

  • Rather than add indications over time, launch with everything from the Phase...

Ricks discussed three strategies that manufacturers might consider to ameliorate the impact of the nine-year timeline, which is industry’s top concern with the design of the program.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

US FDA Will Help States Apply To Import Cheaper Drugs From Canada

 
• By Cathy Kelly

The FDA is not currently signaling that stringent rules for the process will be relaxed, but the agency's change in approach is notable.

Global Pandemic Deal Adopted As 124 Countries Say Yes; US Sits Out

 
• By Neena Brizmohun

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.

HHS Negotiating With Manufacturers On Most Favored Nation Drug Pricing

 
• By Cathy Kelly

MFN policy would would apply to all single source drugs in all insurance markets, according to HHS release. Secretary Robert F. Kennedy Jr. said the department is discussing the plan with drug sponsors.

More from Pink Sheet

UroGen’s Bladder Cancer Drug Draws Split Decision From US FDA Panel

 
• By Sue Sutter

The Oncologic Drugs Advisory Committee voted 5-4 that the overall benefit-risk of UGN-102 is not favorable in patients with recurrent low grade, intermediate-risk, non-muscle invasive bladder cancer and also divided on whether randomized trials should be required for future development programs.

US FDA Will Help States Apply To Import Cheaper Drugs From Canada

 
• By Cathy Kelly

The FDA is not currently signaling that stringent rules for the process will be relaxed, but the agency's change in approach is notable.

Global Pandemic Deal Adopted As 124 Countries Say Yes; US Sits Out

 
• By Neena Brizmohun

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.